Audi, SAIC Launch China Innovation Hub for New AUDI Models 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Add as a preferred source on Google
BUENA, N.J., March 12, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday March 15, 2018 to discuss the 4th quarter 2017 financial results and business update.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to be joined into the Teligent, Inc. call.
This call is being webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
